We’re in that last work week before everyone dashes off. My own clients have headed for the hills (Short Hills?) and I’ve been baking and wrapping this week. It makes me appreciate the usual day to day of policy and reimbursement more than I would have thought. Next week I’ll pull out the vision boards…
Guess which one costs more. This Wall Street Journal article has been making the rounds this week. It highlights how if there are two prices for a drug, plans tend to prefer the higher cost one with higher rebates. I hesitate to call it news because it seems so obvious to those of us who…
InNOvation. Seagen said they aren’t looking at a drug that would treat early-stage bladder cancer because it would be subject to negotiation too soon after approval and wouldn’t have a financial return on the investment. Today the National Pharmaceutical Council published a great piece in Health Affairs that goes deeper into the subject of innovation…
I don’t know if anyone reading this has kids but, in my experience, my kid will start to stretch the boundary on behavior. Small at first. Then three weeks later I realize that everything has gone off the rails and I have to pull in the reigns. It feels like a rubber band that has…
Last week we covered 340B basics. If you missed it, here is a quick summary: There are hospitals, clinics, etc. that serve uninsured individuals. To help care for these patients, the 340B program requires pharmaceutical manufacturers (that wish to participate in the Medicaid program) to sell their products at a massive discount that the entities…
This week Jazz Pharmaceuticals announced that they would no longer be doing bill to/ship to orders on EPIDIOLEX® to contract pharmacies. They became the 25th pharmaceutical manufacturer to place restrictions on 340B sales. By itself this is not huge news (24 companies did it before Jazz) but I also don’t think it should fall into…